Materialise NV (DE:06MA)
NASDAQ:06MA
06MA Stock Chart & Stats
€4.44
€0.25(3.38%)
At close: 4:00 PM EST
€4.44
€0.25(3.38%)
Day’s Range― - ―
52-Week Range€4.10 - €5.90
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€350.57M
Enterprise Value€265.03M
Total Cash (Recent Filing)€132.95M
Total Debt (Recent Filing)€60.13M
Price to Earnings (P/E)33.2
Beta0.67
Next Earnings
Aug 27, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding59,067,184
10 Day Avg. Volume50
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio-0.87
Price to Book (P/B)1.09
Price to Sales (P/S)1.09
P/FCF Ratio30.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.96Price Target Upside56.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.16
Revenue Forecast (FY)€240.45M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Net Cash PositionMaterialise's sizable cash reserves (EUR 133m) and net cash position (EUR 72.8m) with gross debt of EUR 60.1m provide durable financial flexibility. This strengthens the company's ability to fund R&D, absorb demand shocks, execute strategic buybacks, and pursue focused investments over the coming months.
High And Growing Recurring Software RevenueWith ~83% of software revenue recurring and an 88% YoY rise in software adjusted EBITDA, Materialise benefits from more predictable, higher-margin cash flows. The subscription/cloud transition is delivering operating leverage and revenue stability that support durable margin expansion and long-term customer retention.
Medical Segment Growth And Strategic Product LaunchesMedical revenue growth (~7%) and recent launches (PEEK cranio-maxillofacial implants, OrthoView 3D Hip) reinforce a differentiated, higher-value product mix. Healthcare demand, regulatory barriers, and procedural stickiness create a structurally more predictable, higher-margin revenue stream over the medium term.
Bears Say
Cyclicality And Decline In Manufacturing RevenueManufacturing's 8% YoY revenue decline highlights exposure to cyclical prototyping and automotive end markets. That cyclicality can depress capacity utilization and margins, creating near-term top-line volatility and making manufacturing contribution less reliable for sustainable growth over the next several months.
Modest And Volatile Free Cash Flow GenerationTTM free cash flow (~€6.8m) is small and volatile (only ~31% of net income and down year-over-year), indicating limited cash conversion. This constrains reinvestment, weakens buffer versus shocks, and reduces organic funding capacity despite a strong cash balance in the medium term.
Modest Profitability And Low Returns On EquityAlthough gross margins are healthy, net margin (~3.7%) and ROE (~4.1% TTM) remain modest while revenue has slightly declined. This indicates limited ability to convert product economics into strong shareholder returns, constraining capital efficiency and long-term return prospects unless operational leverage improves.
Materialise News
06MA FAQ
What was Materialise NV’s price range in the past 12 months?
Materialise NV lowest stock price was €4.10 and its highest was €5.90 in the past 12 months.
What is Materialise NV’s market cap?
Materialise NV’s market cap is €350.57M.
When is Materialise NV’s upcoming earnings report date?
Materialise NV’s upcoming earnings report date is Aug 27, 2026 which is in 83 days.
How were Materialise NV’s earnings last quarter?
Materialise NV released its earnings results on May 07, 2026. The company reported €0.03 earnings per share for the quarter, beating the consensus estimate of €0.01 by €0.02.
Is Materialise NV overvalued?
According to Wall Street analysts Materialise NV’s price is currently Undervalued.
Does Materialise NV pay dividends?
Materialise NV does not currently pay dividends.
What is Materialise NV’s EPS estimate?
Materialise NV’s EPS estimate is 0.04.
How many shares outstanding does Materialise NV have?
Materialise NV has 59,067,184 shares outstanding.
What happened to Materialise NV’s price movement after its last earnings report?
Materialise NV reported an EPS of €0.03 in its last earnings report, beating expectations of €0.01. Following the earnings report the stock price went down -0.844%.
Which hedge fund is a major shareholder of Materialise NV?
Currently, no hedge funds are holding shares in DE:06MA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Materialise Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.96 (56.84% Upside)
€6.96 (56.84% Upside)
Blogger Sentiment
Bullish
DE:06MA Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.42%
12-Months-Change
Fundamentals
Return on Equity
4.11%
Trailing 12-Months
Asset Growth
14.33%
Trailing 12-Months
Company Description
Materialise NV
Materialise NV provides additive manufacturing and medical software, and 3D printing services in the Americas, Europe and Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. Its Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers and of 3D printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, Website, and third-party distributors. The company's Materialise Medical segment provides medical software that allows medical-image based analysis and engineering, as well as patient-specific design of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, Website, and picture archiving and communication system partners. Its Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to industrial and commercial customers. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
06MA Company Deck
06MA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and financial picture: revenue was stable despite FX headwinds, margins and adjusted profitability improved materially (adjusted EBITDA +>30%, adjusted EBIT up meaningfully), Medical reported solid growth with strategic product launches, software recurring revenue increased and software profitability improved, cash position strengthened, and sustainability and strategic portfolio actions were executed. Offsetting factors include FX-driven reported declines in some areas, an 8% YoY drop in Manufacturing revenue driven by softer prototyping and automotive demand, and the near‑term top‑line impact of divestments. On balance, the favorable profitability trends, cash generation, product and partnership momentum, and reaffirmed guidance outweigh the lowlights.View all DE:06MA earnings summaries06MA Stock 12 Month Forecast
Average Price Target
€6.96
▲(56.84% Upside)
Technical Analysis
Options Prices
Currently, No data available
---